| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Laboratory of Molecular and Tumor Immunology and
Clinical Research, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213;
Departments of Molecular Microbiology and Immunology, and Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239; and
Department of Biology, Lafayette College, Easton, PA 18042
Polarization of the immune response toward a type 1 cytokine profile has been posited to be associated with a therapeutic antitumor immune response. STAT6-/- mice are unable to generate a type 2 immune response, and instead mount an enhanced type 1 response. STAT6-/- mice are significantly more resistant to 4T1, a mammary adenocarinoma cell line, resisting a 10-fold higher tumor dose compared with wild-type (wt) BALB/c mice. An analysis of the T cells from tumor-bearing STAT6-/- mice revealed that they contained a population primed by a peptide (STAT6531–539) of the STAT6 protein expressed in 4T1. The adoptive transfer of T cells from STAT6531–539-vaccinated STAT6-/- mice significantly reduced the number of 4T1 pulmonary metastases in recipient mice. Additionally, the role of these STAT6531–539-reactive T cells against s.c. 4T1 tumor challenge was determined by tumor-challenging wt BALB/c mice reconstituted with STAT6-/- bone marrow, thereby assessing whether a polarized type 1 immune response in the absence of STAT6-reactive T cells was sufficient to reject a 4T1 tumor challenge. T cells from the STAT6-/- bone marrow chimeras failed to recognize the STAT6531–539, and these mice proved to be as susceptible as wt BALB/c mice to 4T1 challenge. This demonstrated that the absence of STAT6531–539-reactive T cells correlated with the inability to reject 4T1 challenge. Additionally, these data emphasize that the enhanced ability to mount a type 1-polarized immune response is inconsequential if a sufficient antitumor immune response is not primed by the tumor.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  W. T. Khaled, E. K. C. Read, S. E. Nicholson, F. O. Baxter, A. J. Brennan, P. J. Came, N. Sprigg, A. N. J. McKenzie, and C. J. Watson The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development Development, August 1, 2007; 134(15): 2739 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Norton, M. Li, N. C. Lee, and K. Tsung Inhibition of Host Signal Transducer and Activator of Transcription Factor 6 Results in Cure With Cyclophosphamide and Interleukin 12 Immunotherapy Ann. Surg. Oncol., January 1, 2006; 13(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti {Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response J. Immunol., March 15, 2005; 174(6): 3281 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease J. Immunol., January 15, 2005; 174(2): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion Cancer Res., December 15, 2004; 64(24): 9124 - 9130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor J. Immunol., April 1, 2004; 172(7): 4026 - 4036. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
